Eli Lilly &reason 04 of 4it makes it for less than anyone else canderived 2026-09-11accession 0000059478-26-000081
Despite explicit price concessions on Mounjaro and Zepbound (including cash-pay cuts and Medicare Bridge discounts), Lilly is expanding gross margin through manufacturing efficiencies and favorable mix. This suggests unit economics remain robust even as list prices decline.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on
“Gross margin as a percent of revenue for the three months ended June 30, 2026 increased 1.5 percentage points, primarily driven by improved cost of production and favorable product mix, partially offset by lower realized prices”
“Gross margin as a percent of revenue for the six months ended June 30, 2026 increased 0.5 percentage points, primarily driven by improved cost of production, partially offset by lower realized prices”
what it was checked against
volume-driven revenue despite price declines
“Revenue increased for the three and six months ended June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices.”
gross margin expansion driving earnings
“Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses.”